"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2017/0313779 A1,156-123-154-087-805,2017-11-02,2017,US 201515523521 A,2015-11-05,US 201515523521 A;;US 201462075491 P;;US 2015/0059135 W,2014-11-05,METHODS AND COMPOSITIONS PERTAINING TO HUMAN CEREBRAL CAVERNOUS MALFORMATIONS,"The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of CCMs in patients, and that blocking those responses treats the CCM. Described herein is a method for treating CCMs in a patient in need thereof comprising administering a therapeutically effective amount of a B-cell immunomodulation therapy to the patient.",UNIV CHICAGO,AWAD ISSAM A,THE UNIVERSITY OF CHICAGO (2017-04-19),https://lens.org/156-123-154-087-805,Patent Application,yes,0,0,2,2,55,A61K39/395;;C07K16/2803;;C07K16/2818;;C07K16/2875;;C07K16/2887;;A61K31/551;;A61K38/1774;;A61P25/00;;A61K39/395;;C07K16/2818;;C07K16/2875;;C07K16/2887;;C07K16/2803;;A61K9/0019;;A61K31/551;;A61K38/1774;;A61K39/3955;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/21;;C07K2317/73;;C07K2319/30;;C07K2319/32,C07K16/28;;A61K9/00;;A61K31/551;;A61K38/17;;A61K39/00;;A61K39/395;;A61K45/06,,0,0,,,,DISCONTINUED
2,WO,A1,WO 2016/073664 A1,027-592-474-337-986,2016-05-12,2016,US 2015/0059135 W,2015-11-05,US 201462075491 P,2014-11-05,METHODS AND COMPOSITIONS PERTAINING TO HUMAN CEREBRAL CAVERNOUS MALFORMATIONS,"The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of CCMs in patients, and that blocking those responses treats the CCM. Described herein is a method for treating CCMs in a patient in need thereof comprising administering a therapeutically effective amount of a B-cell immunomodulation therapy to the patient.",UNIV CHICAGO,AWAD ISSAM A,,https://lens.org/027-592-474-337-986,Patent Application,yes,1,0,2,2,55,A61K39/395;;C07K16/2803;;C07K16/2818;;C07K16/2875;;C07K16/2887;;A61K31/551;;A61K38/1774;;A61P25/00;;A61K39/395;;C07K16/2818;;C07K16/2875;;C07K16/2887;;C07K16/2803;;A61K9/0019;;A61K31/551;;A61K38/1774;;A61K39/3955;;A61K45/06;;A61K2039/505;;A61K2039/507;;C07K16/2878;;C07K2317/21;;C07K2317/73;;C07K2319/30;;C07K2319/32,A61K39/395;;A61P25/00;;C07K16/28,,1,1,013-036-046-973-980,22034008;;pmc3265629;;10.1161/strokeaha.111.625467,"MCDONALD ET AL.: ""Fasudil Decreases Lesion Burden in a Murine Model of Cerebral Cavernous Malformation Disease."", STROKE, vol. 43, no. 2, February 2012 (2012-02-01), pages 571 - 574",PENDING
3,WO,A3,WO 2023/192938 A3,147-478-339-378-496,2023-11-09,2023,US 2023/0065144 W,2023-03-30,US 202263326488 P,2022-04-01,METHODS FOR DETECTING AND TREATING CEREBRAL CAVERNOUS MALFORMATION,"The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from the biomarkers listed in Tables S1-S8 and S13 in a biological sample from the subject. Further aspects relate to A method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from let-7e-5p, miR-93-5p, miR-20b-5p, miR-128-3p, miR-9-5p, IL-10, Tsp-2, IL-2, and TNFR1.",UNIV CHICAGO,AWAD ISSAM;;GIRARD ROMUALD,,https://lens.org/147-478-339-378-496,Search Report,yes,1,0,2,2,0,C12Q1/6883;;A61P7/00;;C12Q2600/178;;C12Q2600/158;;G01N2800/2871;;G01N2800/52;;G01N2333/7151;;G01N2333/55;;G01N33/6896,A61K31/551;;A61K9/00;;A61K31/7105;;A61K39/395;;A61P25/00,,1,1,084-971-511-099-209,35158309;;10.1016/j.ebiom.2022.103880;;pmc8850756,"ZILLE MARIETTA, FARR TRACY D., KEEP RICHARD F., RÖMER CHRISTINE, XI GUOHUA, BOLTZE JOHANNES: ""Novel targets, treatments, and advanced models for intracerebral haemorrhage"", EBIOMEDICINE, ELSEVIER BV, NL, vol. 76, 1 February 2022 (2022-02-01), NL , pages 103880, XP093109218, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2022.103880",PENDING
4,WO,A2,WO 2023/192938 A2,070-308-234-707-261,2023-10-05,2023,US 2023/0065144 W,2023-03-30,US 202263326488 P,2022-04-01,METHODS FOR DETECTING AND TREATING CEREBRAL CAVERNOUS MALFORMATION,"The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from the biomarkers listed in Tables S1-S8 and S13 in a biological sample from the subject. Further aspects relate to A method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from let-7e-5p, miR-93-5p, miR-20b-5p, miR-128-3p, miR-9-5p, IL-10, Tsp-2, IL-2, and TNFR1.",UNIV CHICAGO,AWAD ISSAM;;GIRARD ROMUALD,,https://lens.org/070-308-234-707-261,Patent Application,yes,0,0,2,2,0,C12Q1/6883;;A61P7/00;;C12Q2600/178;;C12Q2600/158;;G01N2800/2871;;G01N2800/52;;G01N2333/7151;;G01N2333/55;;G01N33/6896,C12Q1/6883;;A61K41/00,,0,0,,,,PENDING
